Forest pays $75 million up front for US rights to Almirall LABA
This article was originally published in Scrip
Executive Summary
Forest Laboratories has agreed to pay $75 million up front for US rights to a long-acting beta-agonist in Phase II clinical development for bronchoconstriction in asthmatic patients by Almirall.